文献速递炎症性肠病

人工智能促进临床试验:对炎症性肠病的启示——范围综述

Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-04-10

本范围综述按PRISMA指南检索PubMed中关于人工智能用于临床试验促进的研究,共纳入80篇文章。综述指出人工智能有潜力变革炎症性肠病新药临床开发流程,从候选分子筛选到研究构思与执行,提高试验效率、减少样本量和成本,并辅助患者预筛、入组、监测和终点检测。尽管存在伦理、监管和实践局限,将人工智能纳入临床试验可能加速并提高炎症性肠病药物开发质量。

要点

  • 人工智能可变革炎症性肠病药物临床开发流程,提高试验效率。
  • 人工智能通过改善试验设计质量和促进患者选择,可能帮助减少样本量和成本。
  • 人工智能可能辅助患者预筛以促进并可能自动化试验入组,并改善患者监测。

核心结论

  • 尽管存在伦理、监管和实践局限,将人工智能纳入临床试验可能加速并提高炎症性肠病药物开发质量。

研究设计与样本

  • 范围综述,按照PRISMA范围综述指南进行,检索PubMed中与「人工智能」和「临床试验」相关的术语,共纳入80篇文章。

主要发现

  • 人工智能的快速发展具有巨大潜力变革炎症性肠病新药临床开发流程,从候选分子筛选到研究构思和执行,从而提高试验效率。
  • 通过改善试验设计质量和促进患者选择,人工智能可能帮助减少样本量和成本。
  • 人工智能可能帮助预筛患者以促进并可能自动化试验入组。
  • 人工智能技术还可能通过使依从性控制更准确、促进终点检测和实时分析来帮助患者监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Despite major advances in many fields of science and technology, pharmaceutical research and development continues to be inefficient across multiple diseases. Inflammatory bowel disease (IBD) trials are also subject to high failure rates. The aim of this review was to give an overview of the available literature on the use of artificial intelligence (AI) for clinical trial facilitation across a variety of medical specialties before trying to best position AI in IBD clinical trials. METHODS: A scoping review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) scoping reviews guidelines. The search strategy was performed using PubMed and combined the terms linked to "AI" and "clinical trials." We included studies assessing the use of AI in transforming the key steps of the drug development process and clinical trials. Studies evaluating the use of AI for clinical purposes were excluded. RESULTS: In total, 80 articles were included. The rapid development of AI has great potential to transform the process of clinical development of new drugs in IBD, from screening of candidate molecules to study conception and execution, thereby enhancing trial efficiency. By improving the quality of trial design and facilitating patient selection, AI could help to decrease sample sizes and costs. AI may help to prescreen patients to facilitate-and possibly automate-trial enrollment. AI techniques could also help in patient monitoring by making adherence control more accurate, facilitating endpoint detection and real-time analysis. CONCLUSIONS: Notwithstanding the ethical, regulatory, and practical limitations, incorporation of AI into clinical trials may accelerate and improve quality of drug development in IBD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Le Berre C, Jairath V, Panaccione R, et al. Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review. Clin Gastroenterol Hepatol. 2025. PMID: 40220847. doi:10.1016/j.cgh.2025.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。